WG
ESPR

Winton Group’s Esperion Therapeutics ESPR Stock Holding History

Winton Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,811
Closed -$62.5K – 1267
2026
Q1 		$62.5K Sell
22,811
-35,534
-61% -$112K ﹤0.01% 1061
2025
Q4 		$216K Sell
58,345
-12,551
-18% -$40.6K 0.01% 820
2025
Q3 		$188K Buy
+70,896
New +$137K 0.01% 677
2021
Q2 		– Sell
-7,820
Closed -$219K – 1444
2021
Q1 		$219K Buy
+7,820
New +$231K 0.01% 1253
2018
Q4 		– Sell
-5,148
Closed -$228K – 916
2018
Q3 		$228K Sell
5,148
-2,665
-34% -$122K ﹤0.01% 922
2018
Q2 		$306K Buy
7,813
+66
+0.9% +$3.33K 0.01% 818
2018
Q1 		$560K Buy
+7,747
New +$569K 0.02% 723

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Winton Group's ESPR Position: Q2 2026 in Review

Winton Group sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 22,811 shares — an estimated $62.5K sold.

Winton Group first reported a position in ESPR in Q1 2018 and held it in 7 quarters. The position peaked at $560K in Q1 2018. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Winton Group reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 22,811 Esperion Therapeutics shares in Q2 2026, an estimated $62.5K.
  • Winton Group first reported a position in Esperion Therapeutics in Q1 2018 and held it in 7 quarters.
  • Winton Group's Esperion Therapeutics position peaked at $560K in Q1 2018.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.